精神病学生物标志物研究中异质性的诅咒与机遇。

IF 73.3 1区 医学 Q1 Medicine
World Psychiatry Pub Date : 2023-06-01 DOI:10.1002/wps.21085
Lianne Schmaal
{"title":"精神病学生物标志物研究中异质性的诅咒与机遇。","authors":"Lianne Schmaal","doi":"10.1002/wps.21085","DOIUrl":null,"url":null,"abstract":"271 other and which cluster with a target outcome, using replication to build confidence in an interpretation. Indeed, in the Bipolar and Schizophrenia Network for Intermediate Phenotypes (BSNIP) study, it was the entire biomarker battery which went into defining the final characteristics of the experimental biomarkerdefined entities, which were called “psychosis biotypes”. These biotype constructs have provided research with an alternative to phenomenologically defined entities, as a stage in developing final disease cate gories. Moreover, it is the full biomarker battery which can be ap plied to distinguishing and understanding defined features of the illness, such as negative symptoms. BSNIP researchers have developed several individual studies, now ongoing, to test the clinical applicability of the above biotype constructs. One such study tests the hypothesis that biotype 1, with its low intrinsic EEG activity, is a biomarker which indicates responsiveness to clozapine; specifically, we test the hypothesis that increasing intrinsic EEG activity with clozapine in biotype 1 will correlate with symptomatological improvement, using the attractor network model. A second study, designed to predict treatment response in early psychosis, hypothesizes that the biotypes will define good (biotype 3), moderate (biotype 2) or poor (biotype 1) response to standard coordinated specialty care (CSC). In each of these examples, a doubleblind trial of the biomarker observation (now ongoing) is necessary, and its application can only be supported if this is done with rigorous design. There is no doubt that considerable hard work will have to go into the study of biomarkers in psychiatry before we are able to bring them to a clinically useful place. Yet, the validation of biomarkers, as reviewed in AbiDargham et al’s paper, can be so decisive for the future of our field that these stud ies need to be conducted. Costs have to be born. Yes, wisely; but urgently.","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 2","pages":"271-272"},"PeriodicalIF":73.3000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168170/pdf/WPS-22-271.pdf","citationCount":"0","resultStr":"{\"title\":\"The curse and opportunity of heterogeneity in the pursuit of psychiatric biomarkers.\",\"authors\":\"Lianne Schmaal\",\"doi\":\"10.1002/wps.21085\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"271 other and which cluster with a target outcome, using replication to build confidence in an interpretation. Indeed, in the Bipolar and Schizophrenia Network for Intermediate Phenotypes (BSNIP) study, it was the entire biomarker battery which went into defining the final characteristics of the experimental biomarkerdefined entities, which were called “psychosis biotypes”. These biotype constructs have provided research with an alternative to phenomenologically defined entities, as a stage in developing final disease cate gories. Moreover, it is the full biomarker battery which can be ap plied to distinguishing and understanding defined features of the illness, such as negative symptoms. BSNIP researchers have developed several individual studies, now ongoing, to test the clinical applicability of the above biotype constructs. One such study tests the hypothesis that biotype 1, with its low intrinsic EEG activity, is a biomarker which indicates responsiveness to clozapine; specifically, we test the hypothesis that increasing intrinsic EEG activity with clozapine in biotype 1 will correlate with symptomatological improvement, using the attractor network model. A second study, designed to predict treatment response in early psychosis, hypothesizes that the biotypes will define good (biotype 3), moderate (biotype 2) or poor (biotype 1) response to standard coordinated specialty care (CSC). In each of these examples, a doubleblind trial of the biomarker observation (now ongoing) is necessary, and its application can only be supported if this is done with rigorous design. There is no doubt that considerable hard work will have to go into the study of biomarkers in psychiatry before we are able to bring them to a clinically useful place. Yet, the validation of biomarkers, as reviewed in AbiDargham et al’s paper, can be so decisive for the future of our field that these stud ies need to be conducted. Costs have to be born. Yes, wisely; but urgently.\",\"PeriodicalId\":23858,\"journal\":{\"name\":\"World Psychiatry\",\"volume\":\"22 2\",\"pages\":\"271-272\"},\"PeriodicalIF\":73.3000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168170/pdf/WPS-22-271.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/wps.21085\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/wps.21085","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
The curse and opportunity of heterogeneity in the pursuit of psychiatric biomarkers.
271 other and which cluster with a target outcome, using replication to build confidence in an interpretation. Indeed, in the Bipolar and Schizophrenia Network for Intermediate Phenotypes (BSNIP) study, it was the entire biomarker battery which went into defining the final characteristics of the experimental biomarkerdefined entities, which were called “psychosis biotypes”. These biotype constructs have provided research with an alternative to phenomenologically defined entities, as a stage in developing final disease cate gories. Moreover, it is the full biomarker battery which can be ap plied to distinguishing and understanding defined features of the illness, such as negative symptoms. BSNIP researchers have developed several individual studies, now ongoing, to test the clinical applicability of the above biotype constructs. One such study tests the hypothesis that biotype 1, with its low intrinsic EEG activity, is a biomarker which indicates responsiveness to clozapine; specifically, we test the hypothesis that increasing intrinsic EEG activity with clozapine in biotype 1 will correlate with symptomatological improvement, using the attractor network model. A second study, designed to predict treatment response in early psychosis, hypothesizes that the biotypes will define good (biotype 3), moderate (biotype 2) or poor (biotype 1) response to standard coordinated specialty care (CSC). In each of these examples, a doubleblind trial of the biomarker observation (now ongoing) is necessary, and its application can only be supported if this is done with rigorous design. There is no doubt that considerable hard work will have to go into the study of biomarkers in psychiatry before we are able to bring them to a clinically useful place. Yet, the validation of biomarkers, as reviewed in AbiDargham et al’s paper, can be so decisive for the future of our field that these stud ies need to be conducted. Costs have to be born. Yes, wisely; but urgently.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
World Psychiatry
World Psychiatry Nursing-Psychiatric Mental Health
CiteScore
64.10
自引率
7.40%
发文量
124
期刊介绍: World Psychiatry is the official journal of the World Psychiatric Association. It aims to disseminate information on significant clinical, service, and research developments in the mental health field. World Psychiatry is published three times per year and is sent free of charge to psychiatrists.The recipient psychiatrists' names and addresses are provided by WPA member societies and sections.The language used in the journal is designed to be understandable by the majority of mental health professionals worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信